Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 17;12:959407. doi: 10.3389/fonc.2022.959407

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Horak, Dolnikova, Cumaogullari, Cumova, Navvabi, Vodickova, Levy, Schneiderova, Liska, Andera, Vodicka and Opattova

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

MiR-140 enhances the oxaliplatin sensitivity of CRC cells. (A) CRC cell proliferation after miR-140 and oxaliplatin treatment is decreased after 48 h (p < 0.05) and 72 h (p < 0.05). (B) Analysis of cell clonogenicity potential showed a significant decrease in CFA (p < 0.05). (C) Analysis of cell cycles showed an accumulation of cells in the G1 phase and a decrease in the S phase. The results represent the mean value of three independent experiments ± SD. *p ≤ 0.05. CRC, colorectal cancer; CFA, clonogenicity formation assay.